ClinicalTrials.gg
CompletedNCT05585632Updated Mar 8, 2024

A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old

A Phase 1 interventional study of mRNA-1010 and mRNA-1345 in SARS-CoV-2, Influenza and RSV, sponsored by ModernaTX, Inc.. Completed at 30 sites in 3 countries. Open to participants aged 50 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-08.

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 1, Interventional, and Prevention

From the registry’s dates

  • Primary completion was Feb 2024, 2 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
392
Allocation
Randomized
Ages
50 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human — 2 open to participants now, 2 under way, none of them phase 3. mRNA-1010 influenza vaccine · Influenza, Human.

Enrollment
7th of 12
392 · median 471
Started
2022
with 5 others
Phase 1
3 of 12
1 open now
Registered
6th of 12
by date
Lead sponsor
12 of 12
ModernaTX, Inc.

Among the 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human, this one is the 7th largest by enrollment, is one of 6 that started in 2022, is one of 3 in phase 1, and was the 6th registered.

Influenza, Human

2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

2 of the 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About mRNA-1010 influenza vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.

This study: 50 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human, or all of them as a file.
02

Study summary

The primary goal of this study is to evaluate the safety and reactogenicity of multi-component vaccines mRNA-1045 (Influenza and RSV) and mRNA-1230 (influenza, RSV, and SARS-CoV-2) compared with mRNA-1010 (influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) vaccines in healthy older participants.

03

Conditions studied

  • SARS-CoV-2
  • Influenza
  • RSV

Keywords

  • mRNA-1230 Vaccine
  • mRNA-1045 Vaccine
  • SARS-CoV-2 Vaccine
  • Influenza Vaccine
  • RSV Vaccine
  • Coronavirus
  • Virus Diseases
  • Messenger RNA
  • COVID-19
  • COVID-19 Vaccine
  • Moderna
04

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Investigator assessment that participant understands and is willing and physically able to comply with protocol-mandated follow-up, including all procedures.
  • of 18 to 35 kilograms/square meter (kg/m\^2) (inclusive) at the Screening Visit(s).
  • For female participants of : negative pregnancy test, adequate or has abstained from all activities that could result in pregnancy for at least 28 days prior to Day 1, agreement to continue adequate contraception or abstinence through 3 months following the vaccination, and not currently breastfeeding.
  • Fully vaccinated for COVID-19 with an approved primary series according to the locally authorized or approved regimen. The most recent COVID-19 vaccine (primary series or booster) must be ≥120 days before (or less per local guidance) Day 1.

Exclusion criteria

Exclusion Criteria:

  • Acutely ill or febrile (temperature ≥38.0°Celsius/[100.4°Fahrenheit]) 72 hours before or at the Screening Visit or Day 1. Participants meeting this criterion may be rescheduled within the 28-day screening window for re-evaluation and will retain their initially assigned participant number.
  • Any medical, psychiatric, or occupational condition, including reported history of drug or alcohol abuse, that, in the opinion of the investigator, might pose additional risk due to participation in the study or could interfere with the interpretation of study results.
  • Has received systemic or immune-modifying drugs for >14 days in total within 6 months before screening (for ≥10 milligrams (mg)/day of prednisone or equivalent) or is anticipating the need for immunosuppressive treatment at any time during participation in the study.
  • Received or plans to receive any vaccine authorized or approved by a local health agency ≤28 days before study injections (Day 1) or within 28 days after the study injection.
  • Received a licensed seasonal influenza vaccine or any other influenza or RSV vaccine within ≤180 days before Day 1.
  • Tested positive for influenza or RSV by local health authority-approved testing methods within ≤180 days before Day 1.
  • Significant exposure to someone with SARS-CoV-2 infection or COVID-19 in the past 14 days, as defined by the United States Center for Disease Control (CDC) or the European Centre for Disease Prevention and Control as a high risk (close contact) of a COVID-19 case or known history of SARS-CoV-2 infection within the past 90 days before Day 1.
  • Donated ≥450 mL of blood products within 28 days before the Screening Visit or plans to donate blood products during the study.

Note: Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
392 participants (actual)

Study arms

  • Experimental
    mRNA-1010

    Participants will receive a dose of mRNA-1010 by intramuscular (IM) injection on Day 1.

    Biological: mRNA-1010

  • Experimental
    mRNA-1345

    Participants will receive a dose of mRNA-1345 by IM injection on Day 1.

    Biological: mRNA-1345

  • Experimental
    mRNA-1273.214

    Participants will receive a dose of mRNA-1273.214 by IM injection on Day 1.

    Biological: mRNA-1273.214

  • Experimental
    mRNA-1045 Dose Level A

    Participants will receive mRNA-1045 at Dose Level A by IM injection on Day 1.

    Biological: mRNA-1045

  • Experimental
    mRNA-1045 Dose Level B

    Participants will receive mRNA-1045 at Dose Level B by IM injection on Day 1.

    Biological: mRNA-1045

  • Experimental
    mRNA-1045 Dose Level C

    Participants will receive mRNA-1045 at Dose Level C by IM injection on Day 1.

    Biological: mRNA-1045

  • Experimental
    mRNA-1230 Dose Level A

    Participants will receive mRNA-1230 at Dose Level A by IM injection on Day 1.

    Biological: mRNA-1230

  • Experimental
    mRNA-1230 Dose Level B

    Participants will receive mRNA-1230 at Dose Level B by IM injection on Day 1.

    Biological: mRNA-1230

  • Experimental
    mRNA-1230 Dose Level C

    Participants will receive mRNA-1230 at Dose Level C by IM injection on Day 1.

    Biological: mRNA-1230

Interventions

  • BiologicalmRNA-1010

    Sterile liquid for injection

  • BiologicalmRNA-1345

    Sterile liquid for injection

  • BiologicalmRNA-1273.214

    Sterile liquid for injection

  • BiologicalmRNA-1045

    Formulation for injection

  • BiologicalmRNA-1230

    Formulation for injection

06

What researchers measure

Primary outcomes

  1. Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)

    Time frame: Up to Day 8 (7 days post vaccination)

  2. Number of Participants with Unsolicited Adverse Events (AEs)

    Time frame: Up to Day 29 (28 days post vaccination)

  3. Number of Participants with Medically-Attended AEs (MAAEs)

    Time frame: Day 1 through Day 361

  4. Number of Participants with Adverse Events of Special Interest (AESIs)

    Time frame: Day 1 through Day 361

  5. Number of Participants with Serious Adverse Events (SAEs)

    Time frame: Day 1 through Day 361

  6. Number of Participants with AEs Leading to Discontinuation

    Time frame: Day 1 through Day 361

Secondary outcomes

  1. Change From Baseline in Geometric Mean Titer (GMT) as Measured by Hemagglutination Inhibition (HAI) Assay at Day 29

    Time frame: Baseline (Day 1), Day 29

  2. Change From Baseline in GMT as Measured by Pseudovirus Neutralization Assay (PsVNA) (or Binding Antibody Assay) at Day 29

    Time frame: Baseline (Day 1), Day 29

  3. Change From Baseline in GMT as Measured by Microneutralization Assay at Day 29

    Time frame: Baseline (Day 1), Day 29

  4. Change From Baseline in Geometric Mean Fold-Rise (GMFR) as Measured by HAI Assay at Day 29

    Time frame: Baseline (Day 1), Day 29

  5. Change From Baseline in GMFR as Measured by PsVNA (or Binding Antibody Assay) at Day 29

    Time frame: Baseline (Day 1), Day 29

  6. Change From Baseline in GMFR as Measured by Microneutralization Assay at Day 29

    Time frame: Baseline (Day 1), Day 29

  7. Influenza: Percentage of Participants with Seroconversion as Measured by HAI Assay

    Seroconversion is defined as a Day 29 titer ≥1:40 if baseline is \<1:10 or a 4-fold or greater rise if baseline is ≥1:10 in anti-HA antibodies measured by HAI assay.

    Time frame: Baseline (Day 1) to Day 29

  8. SARS-CoV-2: Percentage of Participants with Seroresponse as Measured by PsVNA (or Binding Antibody Assay)

    Seroresponse is defined as a Day 29 titer ≥4-fold if baseline is ≥lower limit of quantification (LLOQ) or ≥4\*LLOQ if baseline titer is \<LLOQ in nAb titers measured by PsVNA (or binding antibody assay).

    Time frame: Baseline (Day 1) to Day 29

  9. RSV: Percentage of Participants with Seroresponse as Measured by RSV Neutralization Assay

    Seroresponse is defined as a Day 29 titer ≥4-fold if baseline is ≥LLOQ or ≥4\*LLOQ if baseline titer is \<LLOQ in nAb titers measured by RSV neutralization assay.

    Time frame: Baseline (Day 1) to Day 29

07

Study locations

30 sites
  • Accel Research Sites
    DeLand, Florida 32720, United States
  • Research Centers of America (cenexel)
    Hollywood, Florida 33024, United States
  • Accel Research Sites
    Saint Petersburg, Florida 33709, United States
  • Atlanta Center for Medical Research - Family Medicine
    Atlanta, Georgia 30331, United States
  • Centricity Research
    Columbus, Georgia 31904, United States
  • Cenexel IRA (iResearch Atlanta)
    Decatur, Georgia 30030, United States
  • Optimal Research
    Peoria, Illinois 61614, United States
  • DM Clinical Research
    Southfield, Michigan 48076, United States
  • Lucas Research, Inc. (Diabetes & Endocrinology Consultants PC)
    Morehead City, North Carolina 28557, United States
  • Trial Management Associates
    Wilmington, North Carolina 28403, United States
  • Velocity Clinical Research
    Anderson, South Carolina 29621, United States
  • Trial Management Associates
    Myrtle Beach, South Carolina 29572, United States
  • DM Clinical Research
    Houston, Texas 77081, United States
  • DM Clinical Research
    Sugar Land, Texas 77478, United States
  • Paratus Clinical Research Western Sydney
    Blacktown, New South Wales 2148, Australia
  • Paratus Clinical Kanwal
    Kanwal, New South Wales 2259, Australia
  • Paratus Clinical Research Brisbane
    Albion, Queensland 4010, Australia
  • Nucleus Network Brisbane Clinic - Centre For Clinical Studies
    Herston, Queensland 4006, Australia
  • University of the Sunshine Coast
    South Brisbane, Queensland 4101, Australia
  • AusTrials Taringa
    Taringa, Queensland QLD 4068, Australia
  • Emeritus Research
    Camberwell, Victoria 3124, Australia
  • Newcastle University - Institute of Cellular Medicine (ICM)
    Newcastle, England NE2 4HH, United Kingdom
  • Nottingham University Hospitals NHS Trust - Queen's Medical Centre (QMC) Campus
    Nottingham, Nottinghamshire NG7 2UH, United Kingdom
  • University of Oxford
    Oxford, Oxfordshire OX3 7LJ, United Kingdom
  • Bristol Royal Hospital for Children
    Bristol, BS2 8BJ, United Kingdom
  • Royal Devon & Exeter Hospital
    Exeter, EX25DW, United Kingdom
  • Chelsea and Westminster Hospital
    London, SW10 9NH, United Kingdom
  • St George's Healthcare NHS Trust - University of London - Th
    London, SW17 0RE, United Kingdom
  • National Hospital for Neurology and Neurosurgery
    London, WC1N 3GB, United Kingdom
  • Southampton General Hospital
    Southampton, SO16 6YD, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Feb 2024, 16 months.

Of 94 industry-sponsored phase 1 interventional studies under Influenza, Human, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 16 months is above that.

Counting every sponsor, half of 148 studies reached it within 11 months; a quarter within 4 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2022
First posted
Oct 19, 2022
StartActual
Oct 14, 2022
Primary completionActual
Feb 28, 2024
CompletionActual
Feb 28, 2024
Last update
Mar 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05585632
Lead sponsor
ModernaTX, Inc.
Responsible party
Sponsor
First posted
Oct 19, 2022
Start date
Oct 14, 2022
Primary completion
Feb 28, 2024
Completion
Feb 28, 2024
Last update
Mar 8, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: mRNA-1010 influenza vaccine · mRNA-1345 respiratory syncytial virus vaccine · mRNA-1273.214 COVID-19 vaccine

Start the discussion